Rein Therapeutics
RNTX
42 hedge funds and large institutions have $16.5M invested in Rein Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.51% less ownership
Funds ownership: 37.07% → 35.56% (-1.5%)
2% less funds holding
Funds holding: 43 → 42 (-1)
13% less capital invested
Capital invested by funds: $18.9M → $16.5M (-$2.39M)
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$62.7K |
| 2 |
B
Bailard
Foster City,
California
|
+$57.9K |
| 3 |
CG
Colony Group
Boston,
Massachusetts
|
+$40.9K |
| 4 |
Citigroup
New York
|
+$13.6K |
| 5 |
VF
Virtu Financial
New York
|
+$9.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$302K |
| 2 |
Renaissance Technologies
New York
|
-$186K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$151K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$38.4K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$27.5K |
RNTX Hedge Fund Activity: Q1 2022 in Review
42 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2022, worth a combined $16.5M — down 13% from $18.9M a quarter earlier.
Fund positioning in RNTX was balanced in Q1 2022: 7 funds opened new positions, 7 closed out, 5 added to existing stakes and 13 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $62.7K. The largest seller was Morgan Stanley, cutting an estimated $302K.
- 42 institutional investors held Rein Therapeutics (RNTX) as of Q1 2022, down from 43 in Q4 2021.
- Funds reported $16.5M of Rein Therapeutics stock for Q1 2022, down 13% quarter-over-quarter.
- 7 funds opened new Rein Therapeutics positions in Q1 2022 and 7 closed out, a net change of 0 holders.
- The largest Rein Therapeutics buyer in Q1 2022 was Ikarian Capital, an estimated $62.7K added.
- The largest Rein Therapeutics seller in Q1 2022 was Morgan Stanley, an estimated $302K sold.
Based on aggregated 13F filings for Q1 2022.